Maximilian Papi

876 total citations
27 papers, 619 citations indexed

About

Maximilian Papi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Maximilian Papi has authored 27 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Maximilian Papi's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Cancer therapeutics and mechanisms (7 papers). Maximilian Papi is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (11 papers) and Cancer therapeutics and mechanisms (7 papers). Maximilian Papi collaborates with scholars based in Italy and United Kingdom. Maximilian Papi's co-authors include Lucio Crinò, Dino Amadori, Elisa Chiadini, Paola Ulivi, Angelo Delmonte, E. Pasquini, Nicoletta De Luigi, Alessandro Gamboni, Claudio Dazzi and Laura Capelli and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Molecular Sciences.

In The Last Decade

Maximilian Papi

26 papers receiving 602 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maximilian Papi Italy 13 438 371 245 153 63 27 619
Urbano Anido Spain 13 252 0.6× 359 1.0× 172 0.7× 133 0.9× 35 0.6× 67 584
F. Nolè Italy 7 163 0.4× 467 1.3× 269 1.1× 235 1.5× 53 0.8× 12 686
Anh Nguyen Duc Switzerland 7 237 0.5× 797 2.1× 361 1.5× 91 0.6× 49 0.8× 15 925
Jinpeng Shi China 13 446 1.0× 566 1.5× 169 0.7× 261 1.7× 57 0.9× 27 840
Rinat Galiulin United States 6 388 0.9× 370 1.0× 110 0.4× 135 0.9× 39 0.6× 7 556
Mario Liste-Hermoso United States 4 192 0.4× 633 1.7× 298 1.2× 88 0.6× 47 0.7× 7 756
L. Cals France 15 253 0.6× 495 1.3× 102 0.4× 79 0.5× 65 1.0× 41 674
Lambros Vamvakas Greece 17 370 0.8× 597 1.6× 164 0.7× 114 0.7× 41 0.7× 44 759
Marco Angelo Burgio Italy 15 513 1.2× 676 1.8× 115 0.5× 152 1.0× 32 0.5× 44 883
Chia‐Chi Lin Taiwan 11 332 0.8× 326 0.9× 125 0.5× 187 1.2× 56 0.9× 25 637

Countries citing papers authored by Maximilian Papi

Since Specialization
Citations

This map shows the geographic impact of Maximilian Papi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maximilian Papi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maximilian Papi more than expected).

Fields of papers citing papers by Maximilian Papi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maximilian Papi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maximilian Papi. The network helps show where Maximilian Papi may publish in the future.

Co-authorship network of co-authors of Maximilian Papi

This figure shows the co-authorship network connecting the top 25 collaborators of Maximilian Papi. A scholar is included among the top collaborators of Maximilian Papi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maximilian Papi. Maximilian Papi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiadini, Elisa, Matteo Canale, Angelo Delmonte, et al.. (2018). Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). Journal of Thoracic Disease. 10(8). 4858–4864. 2 indexed citations
2.
Dazzi, Claudio, Alessandro Gamboni, Angelo Delmonte, et al.. (2017). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. Journal of Clinical Oncology. 35(15_suppl). e20676–e20676.
3.
Canale, Matteo, Elisabetta Petracci, Angelo Delmonte, et al.. (2016). Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research. 23(9). 2195–2202. 196 indexed citations
4.
5.
Ulivi, Paola, Matteo Canale, Elisabetta Petracci, et al.. (2016). Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.. Journal of Clinical Oncology. 34(15_suppl). 9052–9052. 4 indexed citations
6.
Ulivi, Paola, Elisa Chiadini, Claudio Dazzi, et al.. (2015). Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clinical Lung Cancer. 17(5). 384–390. 75 indexed citations
7.
Tamburini, Emiliano, Lucia Stocchi, Valentina Arcangeli, et al.. (2015). Maintenance bevacizumab versus stop and go therapy after induction therapy in first-line treatment of stage IV colorectal cancer: Pooled analysis of randomized clinical trials.. Journal of Clinical Oncology. 33(15_suppl). e14622–e14622. 1 indexed citations
8.
Tamburini, Emiliano, Lorenzo Gianni, Francesco Maria Drudi, et al.. (2015). Anti-EGFR or Bevacizumab in first line treatment of RAS wild type metastatic colorectal neoplasm (RwtMCRC): meta-analysis of randomized clincal trials. Annals of Oncology. 26. vi36–vi36. 1 indexed citations
9.
Ravaioli, Alessandra, et al.. (2013). Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib. Lung Cancer. 81(2). 294–296. 32 indexed citations
10.
Dazzi, Claudio, Anna Cariello, Cláudia Casanova, et al.. (2012). Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study. Clinical Lung Cancer. 14(1). 28–33. 12 indexed citations
11.
Tassinari, Davide, et al.. (2011). Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. Oncology. 80(5-6). 350–358. 12 indexed citations
12.
Drudi, Fabrizio, et al.. (2011). Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled analysis.. Journal of Clinical Oncology. 29(15_suppl). 4042–4042. 1 indexed citations
13.
Papi, Maximilian, Fabrizio Drudi, Debora Canuti, et al.. (2010). Small cell neuroendocrine tumor of the breast in a 40 year-old woman: a case report. Journal of Medical Case Reports. 4(1). 201–201. 18 indexed citations
14.
Ravaioli, Alessandra, Maximilian Papi, E. Pasquini, et al.. (2009). Lipoplatin™ Monotherapy: A Phase II Trial of Second-Line Treatment of Metastatic Non-Small-Cell Lung Cancer. Journal of Chemotherapy. 21(1). 86–90. 26 indexed citations
15.
16.
Tamburini, Emiliano, Maximilian Papi, E. Pasquini, et al.. (2006). Palliative treatment with gefitinib (G) in advanced and heavy pre-treated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17139–17139. 1 indexed citations
17.
Tassinari, Davide, Giovenzio Genestreti, E. Pasquini, et al.. (2005). Efficacy of Two Different Platinum- or Anthracycline- Containing Chemotherapy Regimens for the Treatment of Small Cell Lung Cancer. Journal of Chemotherapy. 17(2). 228–236. 2 indexed citations
18.
Ravaioli, Alberto, Elena Pasini, Maximilian Papi, et al.. (2002). Staging of Breast Cancer: New Recommended Standard Procedure. Breast Cancer Research and Treatment. 72(1). 53–60. 66 indexed citations
19.
Pasquini, E., Paolo Rinaldi, Mario Nicolini, et al.. (2000). Breast involvement in immunolymphoproliferative disorders: Report of two cases of multiple myeloma of the breast. Annals of Oncology. 11(10). 1353–1360. 9 indexed citations
20.
Ravaioli, Alessandra, Davide Tassinari, Elena Pasini, et al.. (1998). Staging of breast cancer: What standards should be used in research and clinical practice?. Annals of Oncology. 9(11). 1173–1177. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Urbano Anido Breakdown of academic impact, for papers by F. Nolè Breakdown of academic impact, for papers by Anh Nguyen Duc Breakdown of academic impact, for papers by Jinpeng Shi Breakdown of academic impact, for papers by Rinat Galiulin Breakdown of academic impact, for papers by Mario Liste-Hermoso Breakdown of academic impact, for papers by L. Cals Breakdown of academic impact, for papers by Lambros Vamvakas Breakdown of academic impact, for papers by Marco Angelo Burgio Breakdown of academic impact, for papers by Chia‐Chi Lin
Rankless by CCL
2026